What is Unlearn.AI?
Founded in 2017 by former Pfizer principal scientist Charles Fisher, Unlearn.AI operates at the intersection of deep tech and life sciences. The company is recognized for its proprietary digital twin technology, which creates longitudinal, computationally generated clinical records to simulate placebo control groups. This approach effectively replaces the need for traditional placebo cohorts, thereby reducing the number of human participants required for clinical trials and increasing the statistical power of exploratory analyses.
Currently, the firm is concentrating its efforts on high-unmet-need therapeutic areas, specifically Alzheimer's disease and multiple sclerosis. By integrating real-world patient data with predictive modeling, Unlearn.AI provides pharmaceutical developers with a robust framework to understand individual patient responses to experimental treatments, effectively mitigating the risks associated with trial variability and accelerating the path to regulatory approval.
How much funding has Unlearn.AI raised?
Unlearn.AI has raised a total of $180M across 5 funding rounds:
Series A
$15M
Other Financing Round
$15M
Multiple Rounds
$150M
Series A (2020): $15M with participation from DCVC, DCVC Bio, Eisai, 8VC, and Mubadala Capital Ventures
Other Financing Round (2023): $15M led by Radical Ventures and Wittington Ventures
Series C (2024): $50M supported by Wittington Ventures, Radical Ventures, Mubadala, and Altimeter Capital
Series C (2024): $50M featuring Altimeter Capital, Radical Ventures, Mubadala, and Wittington Ventures
Series C (2024): $50M backed by Altimeter Capital, Radical Ventures, Wittington Ventures, and Mubadala
Key Investors in Unlearn.AI
Radical Ventures
A venture capital firm specializing in early-stage and growth-stage investments in artificial intelligence and deep technology, founded by the architects of the Vector Institute.
Wittington Ventures
A private family investment firm based in Canada with a diverse portfolio spanning retail, real estate, and strategic technology ventures.
Altimeter Capital
An investment firm that partners with technology companies from early growth through public markets, focusing on long-term value creation and strategic product development.
What's next for Unlearn.AI?
With the successful closure of its latest funding round, Unlearn.AI is well-positioned to expand the reach of its DiGenesis platform across broader therapeutic indications. The strategic focus will likely shift toward scaling operations and deepening partnerships with global pharmaceutical entities to standardize the use of digital twins in regulatory-grade clinical trials. As the company matures, the emphasis will remain on demonstrating the long-term efficacy of its computational models in reducing trial timelines and costs. The continued support from institutional investors suggests a clear trajectory toward becoming an essential component of the modern clinical research ecosystem, potentially setting a new industry standard for trial design and patient-centric drug development.
See full Unlearn.AI company page
